ATE188708T1 - Antikörperderivate - Google Patents
AntikörperderivateInfo
- Publication number
- ATE188708T1 ATE188708T1 AT92810633T AT92810633T ATE188708T1 AT E188708 T1 ATE188708 T1 AT E188708T1 AT 92810633 T AT92810633 T AT 92810633T AT 92810633 T AT92810633 T AT 92810633T AT E188708 T1 ATE188708 T1 AT E188708T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- antibodies derivatives
- antibodies
- derivatives
- hiv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919118013A GB9118013D0 (en) | 1991-08-21 | 1991-08-21 | Monoclonal antibodies and their use |
GB929204514A GB9204514D0 (en) | 1992-03-02 | 1992-03-02 | Monoclonal antibodies and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE188708T1 true ATE188708T1 (de) | 2000-01-15 |
Family
ID=26299429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92810633T ATE188708T1 (de) | 1991-08-21 | 1992-08-18 | Antikörperderivate |
Country Status (10)
Country | Link |
---|---|
US (1) | US5562903A (de) |
EP (1) | EP0528767B1 (de) |
JP (1) | JP3474592B2 (de) |
AT (1) | ATE188708T1 (de) |
CA (1) | CA2076432C (de) |
DE (1) | DE69230545T2 (de) |
DK (1) | DK0528767T3 (de) |
ES (1) | ES2145004T3 (de) |
GR (1) | GR3032944T3 (de) |
PT (1) | PT528767E (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07507207A (ja) * | 1992-05-22 | 1995-08-10 | ノバルティス・アクチエンゲゼルシャフト | ルイスy−特異的モノクローナル抗体br55−2に対する抗イディオタイプモノクローナル抗体およびその使用 |
US6310185B1 (en) * | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
EP0781847A1 (de) * | 1995-11-06 | 1997-07-02 | MERCK PATENT GmbH | Humanisierter monoklonaler Antikörper |
AU2527397A (en) * | 1996-03-13 | 1997-10-01 | Protein Design Labs, Inc. | Fas ligand fusion proteins and their uses |
US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
CZ20012925A3 (cs) * | 1999-02-12 | 2002-01-16 | Genetics Institute, Inc. | Humanizovaný imunoglobulin reaktivní s B7 molekulami a způsob léčení |
AR022952A1 (es) | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7390885B2 (en) | 2001-11-26 | 2008-06-24 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
US7365167B2 (en) | 2001-11-26 | 2008-04-29 | Cell Matrix, Inc. | Humanized collagen antibodies and related methods |
US20080063639A1 (en) * | 2002-01-18 | 2008-03-13 | Pierre Fabre Medicament | Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies |
AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
AT413487B (de) | 2002-08-12 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung von antikörpern gegen ein tumor-assoziiertes antigen |
AT500648B1 (de) | 2002-08-12 | 2010-03-15 | Igeneon Krebs Immuntherapie | Set zur behandlung von krebspatienten |
US7780992B2 (en) * | 2002-12-08 | 2010-08-24 | Tareq Abduljalil Albahri | Antiviral medicament |
TW200539855A (en) * | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
US7759464B2 (en) | 2004-07-14 | 2010-07-20 | Greenovation Biotech Gmbh | N-glycosylated antibody |
AU2006208226A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
EP1844074B1 (de) * | 2005-02-03 | 2013-04-24 | Antitope Limited | Menschliche antikörper und proteine |
US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
BRPI0711908B8 (pt) | 2006-05-25 | 2021-05-25 | Glaxo Group Ltd | anticorpo anti-interleucina-18 humanizado, composição farmacêutica, uso de um anticorpo anti-interleucina 18, e, método de produção de um anticorpo. |
TWI429658B (zh) * | 2006-06-07 | 2014-03-11 | Bioalliance Cv | 辨認癌症細胞上表現的cd43與cea之含碳水化合物抗原決定區的抗體及其使用方法 |
EP1878747A1 (de) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-hergestellte Antikörper |
US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
AT504231A1 (de) | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
JP2010513539A (ja) * | 2006-12-20 | 2010-04-30 | エムエムアール インフォメーション システムズ,インコーポレーテッド | 抗体とその製造法および使用法 |
US8974791B2 (en) | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
CN101918448A (zh) | 2007-12-18 | 2010-12-15 | 生物联合公司 | 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法 |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
CA2710984C (en) * | 2007-12-28 | 2018-05-29 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
EP2894226B1 (de) * | 2009-01-08 | 2021-04-14 | Bio-Rad Laboratories, Inc. | Verfahren und zusammensetzung zur verbesserung der wirksamkeit bei einer nukleinsäureverstärkungsreaktion |
EP2408474B1 (de) | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Zusammensetzungen und verfahren zur verabreichung von igg-köderrezeptor-fusionsproteinen in die blut-hirn-schranke |
ES2725200T3 (es) * | 2009-10-09 | 2019-09-20 | Armagen Inc | Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC |
JP6166177B2 (ja) * | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Cd47に対するヒト化及びキメラモノクローナル抗体 |
EP2407487A1 (de) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispezifische modulare Antikörper |
JP2012067106A (ja) * | 2011-10-14 | 2012-04-05 | Greenovation Biotech Gmbh | グリコシル化抗体 |
CA2857647C (en) | 2011-12-02 | 2022-04-19 | Armagen Technologies, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
WO2017216724A1 (en) | 2016-06-15 | 2017-12-21 | Novartis Ag | Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6) |
CN109266656B (zh) * | 2018-10-10 | 2021-02-19 | 江苏集萃药康生物科技股份有限公司 | 一种PD1人源化BALB/c小鼠模型的构建方法及其应用 |
GB201910899D0 (en) * | 2019-07-31 | 2019-09-11 | Scancell Ltd | Binding members |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) * | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
ATE143052T1 (de) * | 1986-07-07 | 1996-10-15 | Centocor Inc | Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen |
US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
US4978745A (en) * | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE4006308A1 (de) * | 1990-02-28 | 1991-08-29 | Sandoz Ag | Verwendung des monoklonalen antikoerpers br 55.2 gegen kleinzelliges lungenkarzinom |
DE4025499A1 (de) * | 1990-08-11 | 1992-02-13 | Sandoz Ag | Verwendung der antikoerper br55-2, deren derivate, konjugate und fragmente zur bekaempfung von hiv-infektionen |
-
1992
- 1992-08-18 DE DE69230545T patent/DE69230545T2/de not_active Expired - Lifetime
- 1992-08-18 EP EP92810633A patent/EP0528767B1/de not_active Expired - Lifetime
- 1992-08-18 ES ES92810633T patent/ES2145004T3/es not_active Expired - Lifetime
- 1992-08-18 PT PT92810633T patent/PT528767E/pt unknown
- 1992-08-18 DK DK92810633T patent/DK0528767T3/da active
- 1992-08-18 AT AT92810633T patent/ATE188708T1/de active
- 1992-08-19 CA CA002076432A patent/CA2076432C/en not_active Expired - Lifetime
- 1992-08-20 JP JP22136192A patent/JP3474592B2/ja not_active Expired - Lifetime
-
1993
- 1993-04-22 US US08/053,171 patent/US5562903A/en not_active Expired - Lifetime
-
2000
- 2000-03-10 GR GR20000400640T patent/GR3032944T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PT528767E (pt) | 2000-06-30 |
EP0528767A1 (de) | 1993-02-24 |
ES2145004T3 (es) | 2000-07-01 |
DE69230545T2 (de) | 2000-07-06 |
CA2076432A1 (en) | 1993-02-22 |
US5562903A (en) | 1996-10-08 |
DE69230545D1 (de) | 2000-02-17 |
CA2076432C (en) | 2003-10-21 |
JP3474592B2 (ja) | 2003-12-08 |
GR3032944T3 (en) | 2000-07-31 |
JPH05336989A (ja) | 1993-12-21 |
DK0528767T3 (da) | 2000-04-17 |
EP0528767B1 (de) | 2000-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE188708T1 (de) | Antikörperderivate | |
DE68923027D1 (de) | Antigene. | |
IT9068053A0 (it) | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi e terapia di affezioni tumorali e suo impiego | |
DK69890A (da) | Monoklonale antistoffer, der er reaktive med cachetin | |
DE3783277T2 (de) | Monoklonaler antikoerper gegen humanes lungenkarzinom. | |
GR3026219T3 (en) | Mouse monoclonal antibodies | |
OA08485A (fr) | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas. | |
EP0198086A4 (de) | Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikörpern, deren herstellung und antivirale menschliche monoklonale antikörper. | |
NO870476L (no) | Fremgangsmaate for fremstilling av kryss-beskyttende humane monoklonale antistoffpreparater. | |
DE3485712D1 (de) | Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren. | |
AU5583286A (en) | E87ag antigen of pseudomonas aeruginosa, monoclonal antibody against it, and hybridoma | |
ATE137674T1 (de) | Von mca 16-88 erkanntes antigen | |
DE69119591T2 (de) | Das von mca-28a32 erkannte antigen | |
DK513687D0 (da) | Monoklonale antistoffer over for ifn-omega, fremgangsmaade til deres fremstilling og deres anvendelse til rensning samt paavisning af ifn-omega | |
FI945485A (fi) | Monoklonaaliset vasta-aineet ja niiden käyttö | |
DE69232140D1 (de) | Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind | |
EP0334076A3 (en) | Monoclonal antibody capable of recognizing an antigen associated with human arteriosclerosis, and process for preparing the same | |
NO924803L (no) | Tumor-relatert monoklonalt antistoff 88bv59 | |
DE68913601D1 (de) | Monoklonaler Antikörper gegen menschliches Lungenadenokarzinom. | |
NO952506L (no) | Antistoffpreparater mot homogent minaktivin og anvendelse derav for påvisning av minaktivin i humane kroppsvæsker | |
DE3882066T2 (de) | Monoclonaler Antikörper gegen menschliches Lungenadenokarzinom. | |
AU2687992A (en) | Sf-25 antibodies, especially chimeric antibodies, with specificity for the human tumor sf-25 antigen, methods for their production, and uses thereof | |
DE68913872T2 (de) | Monoklonale Antikörper gegen den menschlichen Epidermal-Wachstumsfaktor mit hohem Molekulargewicht. | |
MX9705445A (es) | Anticuerpos monoclonales anti-cd6 y su usos. | |
ATE169332T1 (de) | Monoklonaler antikörper gegen den extravillösen trophoblast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |